Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial investigates cetuximab addition to FOLFOX-4 for improved outcomes in metastatic colorectal cancer, suggesting KRAS status guides treatment.
Key Points
- This study aims to compare the overall response rates of cetuximab combined with FOLFOX-4 versus FOLFOX-4 alone in patients with metastatic colorectal cancer while examining KRAS mutation status.
- 169 patients received cetuximab plus FOLFOX-4 and 168 received FOLFOX-4 alone.
- Treatment continued until disease progression or unacceptable toxicity.
- KRAS mutation status was assessed in 233 patients with assessable tumor samples.
- The confirmed overall response rate for cetuximab plus FOLFOX-4 was 46% compared to 36% for FOLFOX-4 alone.
- In KRAS wild-type tumors, ORR was significantly greater with cetuximab (61% vs 37%, OR 2.54, P = .011) and associated with a lower risk of progression (HR 0.57, P = .0163).
- Addition of cetuximab to FOLFOX-4 was well tolerated.
Cite This Study
Bokemeyer et al. (2008) studied this question.